Skip to Content

'
Jieru Meng, Ph.D.

Present Title & Affiliation

Primary Appointment

Instructor, Department of Thoracic and Cardiovascular Surgery - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1489
Houston, TX 77030
Room Number: T4.3895

Education & Training

Degree-Granting Education

2005 The Fourth Military Medical University, Xi'an, China, PHD, Biochemistry and Molecular Biology
2002 The Fourth Military Medical University, Xi'an, China, MS, Aerospace and Navigation Medicine

Postgraduate Training

2007-2010 Postdoctoral Fellowship, The University of Texas MD Anderson Cancer Center, Department of Thoracic and Cardiovascular Surgery, Houston, TX, Dr. Bingliang Fang
2006-2007 Postdoctoral Fellowship, The University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, Dr. David A. Boothman

Professional Memberships

American Association of Cancer Research
Associate Member, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71(10):3658-68, 5/15/2011. e-Pub 3/28/2011. PMCID: PMC3392199.
2. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5(11):e14124, 2010. e-Pub 11/29/2010. PMCID: PMC2993951.
3. Meng J, Peng H, Dai B, Guo W, Wang L, Ji L, Minna JD, Chresta CM, Smith PD, Fang B, Roth JA. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 8(21):2073-80, 11/2009. e-Pub 11/2009. PMCID: PMC2835993.
4. Meng J, Yan Z, Wu Y, Gao M, Li W, Gao F, Wang H, Han W, Zhang Y. Preclinical safety evaluation of IFNalpha2a-NGR. Regul Toxicol Pharmacol 50(3):294-302, 4/2008. e-Pub 11/2007. PMID: 18316145.
5. Meng J, Yan Z, Wu J, Li L, Xue X, Li M, Li W, Hao Q, Wan Y, Qin X, Zhang C, You Y, Han W, Zhang Y. High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a. Cytotherapy 9(1):60-8, 2007. PMID: 17354103.

Last updated: 12/10/2012